Skip to main content
SpringerLink
Log in
Book cover

Mesothelioma pp 271–280Cite as

Immunotherapy of Mesothelioma: Vaccines and Cell Therapy

A Focus on Dendritic Cell Therapy

  • Chapter
  • First Online:

Abstract

Malignant pleural mesothelioma is a lethal cancer with a moderate response to registered treatment. Current first-line treatment consists of a combination of platinum-based chemotherapy and an antifolate agent and leads to an overall survival of 9–12 months. Concurrent treatment with bevacizumab in addition to first-line treatment leads to a survival benefit of 2 months. Immunotherapy, namely checkpoint inhibition, has impacted the treatment of various cancer types drastically. In mesothelioma, promising clinical results with these antibodies have been shown, but only in a minority of patients and responses are not durable. This seems related to the absence of an activate T cell response to the tumor. Vaccination or T cell therapy may be used as strategies to increase tumor-directed T cells and in this way activate the immune system toward the tumor. Although elaborate investigations are ongoing numerous randomized trials are currently underway and more are planned to investigate the efficacy of these novel treatments.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475–88.

    Article  CAS  Google Scholar 

  2. Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v31–9.

    Article  Google Scholar 

  3. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408.

    Article  CAS  Google Scholar 

  4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:2636–44.

    Article  CAS  Google Scholar 

  5. Ricciardi S, Cardillo G, Zirafa C, et al. Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis. 2018;10:S285.

    Article  Google Scholar 

  6. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–72.

    Article  Google Scholar 

  7. Bronte G, Incorvaia L, Rizzo S, et al. The resistance related to targeted therapy in malignant pleural mesothelioma: why has not the target been hit yet? Crit Rev Oncol Hematol. 2016;107:20–32.

    Article  Google Scholar 

  8. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.

    Article  CAS  Google Scholar 

  9. Scagliotti GV, Gaafar R, Nowak AK, et al. LUME-Meso: design and rationale of the phase III part of a placebo-controlled study of Nintedanib and Pemetrexed/Cisplatin followed by maintenance Nintedanib in patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2017;18:589–93.

    Article  CAS  Google Scholar 

  10. Fennell DA, Kirkpatrick E, Cozens K, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19:233.

    Article  Google Scholar 

  11. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13:5144–9.

    Article  CAS  Google Scholar 

  12. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15:5274–9.

    Article  CAS  Google Scholar 

  13. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1467–79.

    Article  CAS  Google Scholar 

  14. Petrausch U, Schuberth PC, Hagedorn C, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012;12:615.

    Article  CAS  Google Scholar 

  15. Sigalotti L, Coral S, Altomonte M, et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 2002;86:979–82.

    Article  CAS  Google Scholar 

  16. Watanabe Y, Kojima T, Kagawa S, et al. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene. 2010;29:1145–54.

    Article  CAS  Google Scholar 

  17. Cornelissen R, Hegmans J, Maat A, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016;193:1023–31.

    Article  CAS  Google Scholar 

  18. Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 2017;38:577–93.

    Article  CAS  Google Scholar 

  19. Garg AD, Vara Perez M, Schaaf M, et al. Trial watch: dendritic cell-based anticancer immunotherapy. Oncoimmunology. 2017;6:e1328341.

    Article  Google Scholar 

  20. Eguchi T, Kadota K, Mayor M, et al. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017;8:77872–82.

    Article  Google Scholar 

  21. Zauderer MG, Tsao AS, Dao T, et al. A randomized phase II trial of adjuvant Galinpepimut-S, WT-1 Analog peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017;23:7483–9.

    Article  CAS  Google Scholar 

  22. Claesson MH. Why current peptide-based cancer vaccines fail: lessons from the three Es. Immunotherapy. 2009;1:513–6.

    PubMed  Google Scholar 

  23. Dammeijer F, Lievense LA, Veerman GD, et al. Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3204–12.

    Article  CAS  Google Scholar 

  24. Schreibelt G, Bol KF, Westdorp H, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res. 2016;22:2155–66.

    Article  CAS  Google Scholar 

  25. Berneman Z, Van de Velde A, Anguille S, et al. Vaccination with Wilms’ tumor antigen (<em>WT1)</em> mRNA-Electroporated dendritic cells as an adjuvant treatment in 60 cancer patients: report of clinical effects and increased survival in acute myeloid Leukemia, metastatic breast cancer, glioblastoma and mesothelioma. Cytotherapy. 2016;18:S13–4.

    Article  Google Scholar 

  26. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181:1383–90.

    Article  CAS  Google Scholar 

  27. Hegmans JPJJ, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate–pulsed dendritic cells. Am J Respir Crit Care Med. 2005;171:1168–77.

    Article  Google Scholar 

  28. Aerts JG, Goeje P, Cornelissen R, et al. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res. 2017;24:766–76.

    Article  Google Scholar 

  29. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol. 2013;4:371.

    Article  Google Scholar 

  30. Klampatsa A, Haas AR, Moon EK, Albelda SM. Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM). Cancers. 2017;9:115.

    Article  Google Scholar 

  31. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.

    Article  Google Scholar 

  32. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–76.

    Article  CAS  Google Scholar 

  33. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15:e257–67.

    Article  CAS  Google Scholar 

  34. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60.

    Article  CAS  Google Scholar 

  35. Veltman JD, Lambers MEH, van Nimwegen M, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:1–13.

    Article  Google Scholar 

  36. Dammeijer F, Lau SP, Eijck C, Burg S, Aerts JGJV. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine Growth Factor Rev. 2017;36:5–15.

    Article  CAS  Google Scholar 

  37. Steendam CMJ, Dammeijer F, Aerts JGJV, Cornelissen R. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. Immunotherapy. 2017;9:507–20.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands

    R. A. Belderbos, R. Cornelissen & J. G. J. V. Aerts

  2. Erasmus MC Cancer Institute, Erasmus MC Rotterdam, Rotterdam, The Netherlands

    R. A. Belderbos, R. Cornelissen & J. G. J. V. Aerts

Authors
  1. R. A. Belderbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Cornelissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. G. J. V. Aerts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. G. J. V. Aerts .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Giovanni Luca Ceresoli

  2. Scientific Direction, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  3. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

    Maurizio D'Incalci

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Belderbos, R.A., Cornelissen, R., Aerts, J.G.J.V. (2019). Immunotherapy of Mesothelioma: Vaccines and Cell Therapy. In: Ceresoli, G., Bombardieri, E., D'Incalci, M. (eds) Mesothelioma. Springer, Cham. https://doi.org/10.1007/978-3-030-16884-1_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16884-1_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16883-4

  • Online ISBN: 978-3-030-16884-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation